Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

CELL COMPOSITIONS COMPRISING ANTIGEN-SPECIFIC T CELLS FOR ADOPTIVE THERAPY

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Publication Date:
    December 14, 2023
  • Additional Information
    • Document Number:
      20230399613
    • Appl. No:
      17/989905
    • Application Filed:
      November 18, 2022
    • Abstract:
      The present invention provides an isolated cell composition suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s). In various embodiments, the composition is predominately CD8+ T cells, and at least about 20% of T cells in the composition exhibit a central or effector memory phenotype, providing for a robust and durable adoptive therapy from a natural T cell repertoire that has undergone natural selection.
    • Claim:
      1. An isolated cell composition suitable for adoptive immunotherapy, the composition comprising, in a pharmaceutically acceptable carrier: at least 106 CD8+ T cells specific for one or more target peptide antigens, wherein at least 20% of T cells in the composition exhibit a central memory or effector memory phenotype.
    • Claim:
      2-3. (canceled)
    • Claim:
      4. The isolated cell composition of claim 1, wherein the target peptide antigens are tumor associated antigens.
    • Claim:
      5. (canceled)
    • Claim:
      6. The isolated cell composition of claim 1, wherein one or more target peptide antigens are bacterial, viral, fungal, or parasitic antigens.
    • Claim:
      7. The isolated cell composition of claim 1, comprising CD8+ T cells specific for at least one, two, three, four, or five target peptide antigens.
    • Claim:
      8-10. (canceled)
    • Claim:
      11. The isolated cell composition of claim 1, wherein the cell composition is at least 5% CD8+ T cells specific for the target peptide antigens.
    • Claim:
      12-13. (canceled)
    • Claim:
      14. The isolated cell composition of claim 4, wherein the cell composition further comprises CD8+ T cells specific for bacterial, viral, and/or fungal pathogens.
    • Claim:
      15. The isolated cell composition of claim 14, wherein the CD8+ T cells specific for bacterial, viral, or fungal pathogens include T cells specific for antigens of influenza, CMV, EBV, and/or adenovirus.
    • Claim:
      16. The isolated cell composition of claim 1, wherein the T cells are at least 30% central and effector memory T cells.
    • Claim:
      17. The isolated cell composition of claim 16, wherein the T cells are at least 50% central and effector memory T cells.
    • Claim:
      18-19. (canceled)
    • Claim:
      20. The isolated cell composition of claim 16, wherein the T cells specific for the one or more target antigens are at least 50% central and effector memory T cells.
    • Claim:
      21-26. (canceled)
    • Claim:
      27. The isolated cell composition of claim 1, wherein the T cells are less than 20% terminally differentiated.
    • Claim:
      28-29. (canceled)
    • Claim:
      30. The isolated cell composition of claim 1, wherein the composition comprises less than 20% naive cells.
    • Claim:
      31-33. (canceled)
    • Claim:
      34. The isolated composition of claim 1, further comprising T memory stem cells.
    • Claim:
      35. (canceled)
    • Claim:
      36. The isolated cell composition of claim 1, wherein the CD8+ T cells display a polyfunctional phenotype upon activation.
    • Claim:
      37. The isolated cell composition of claim 1, wherein the cell composition is less than 10% CD4+ T cells.
    • Claim:
      38-42. (canceled)
    • Claim:
      43. The cell composition of claim 1, wherein the composition is produced by enrichment of CD8+ T cells specific for the target peptide antigens from source cells; and/or expansion of CD8+ T cells specific for the target peptide antigens from source cells.
    • Claim:
      44-50. (canceled)
    • Claim:
      51. The isolated cell composition of claim 43, wherein the antigen-specific T cells are enriched by aAPCs having an MHC class I ligand and optionally a co-stimulatory ligand.
    • Claim:
      52-53. (canceled)
    • Claim:
      54. The isolated cell composition of claim 43, wherein the enrichment is magnetic enrichment with paramagnetic aAPCs, and wherein the cells and aAPCs are incubated in the presence of a magnetic field for at least one minute.
    • Claim:
      55-57. (canceled)
    • Claim:
      58. The isolated cell composition of claim 43, wherein the enriched cells are expanded in culture for from 1 to 4 weeks.
    • Claim:
      59. The isolated cell composition of claim 58, wherein the cells are expanded in culture in the presence of one or more, two or more, or three or more of MIP-1β, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-15, IL-21, and INF-γ, and IL-10.
    • Claim:
      60-62. (canceled)
    • Claim:
      63. The isolated cell composition of claim 59, wherein the cells are expanded in the presence of IL-4.
    • Claim:
      64. The isolated cell composition of claim 59, wherein the cells are expanded in the presence of IL-4 and IL-6.
    • Claim:
      65. The isolated cell composition of claim 59, wherein the cells are expanded in the presence of IL-4 and IL-1β.
    • Claim:
      66. The isolated cell composition of claim 59, wherein the cells are expanded in the presence of IL-4, IL-6, and IL-1β.
    • Claim:
      67. The isolated cell composition of claim 59, wherein the cells are expanded in the presence of IL-2, IL-4, and IL-6.
    • Claim:
      68. The isolated cell composition of claim 59, wherein the cells are expanded in culture in the presence of IL-2, IL-4, IL-6, INF-γ, and IL-1β.
    • Claim:
      69-70. (canceled)
    • Claim:
      71. An isolated cell composition suitable for adoptive immunotherapy, the composition comprising, in a pharmaceutically acceptable carrier: at least 90% CD8+ T cells and less than 5% CD4+ T cells; the CD8+ cells comprising at least 106 CD8+ T cells specific for from 1 to 10 target peptide antigens, and CD8+ T cells specific for bacterial, viral, fungal and/or parasitic pathogens, wherein at least 30% of the CD8+ T cells are central memory and effector memory T cells with a ratio of from 25:75 to 75:25, with less than 10% of the CD8+ T cells being terminally differentiated T cells and less than 10% of the CD8+ cells being naive cells; and wherein at least 50% of the CD8+ T cells specific for the target peptide antigens are central memory and effector memory T cells with a ratio of from 25:75 to 75:25, are less than 10% terminally differentiated T cells, and are less than 10% naive cells.
    • Claim:
      72-74. (canceled)
    • Claim:
      75. The isolated cell composition of claim 71, further comprising from 5% to about 20% T memory stem cells.
    • Claim:
      76. The isolated cell composition of claim 71, wherein the target peptide antigens are tumor associated antigens, and are associated with hematological malignancy.
    • Claim:
      77. (canceled)
    • Claim:
      78. A method for treating a patient with cancer, comprising administering the cell composition of claim 1 to a patient in need.
    • Claim:
      79-83. (canceled)
    • Claim:
      84. A method for manufacturing the cell composition of claim 1, comprising: depletion of CD4+ T cells from source cells; enrichment of CD8+ T cells specific for the one or more target peptide, wherein the enrichment is magnetic enrichment with paramagnetic aAPCs; and expansion of the CD8+ T cells ex vivo, wherein the CD8+ T cells are expanded in culture in the presence of one or more, two or more, or three or more of MIP-1β, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-15, IL-21, and IFN-γ.
    • Current International Class:
      12; 61; 61; 12; 61
    • Accession Number:
      edspap.20230399613